Sherry Li, Ph.D.

Sherry Li is a seasoned pharma data strategist with over two decades of experience

spanning competitive intelligence, licensing evaluation, and clinical data strategy. She has supported both global pharmaceutical companies and emerging biotechs in asset assessment, development planning, and strategic positioning.

Before joining the firm, Sherry led strategic initiatives at Roche in competitive intelligence and asset evaluation, supporting license-in decisions across oncology and immunology. She also advised early-stage biotech companies on biomarker strategy, trial design, and metadata readiness. At Bristol Myers Squibb, Sherry led a team applying AI and NLP to extensive historical clinical trial data, generating insights that informed protocol design, feasibility assessment, and asset evaluation for licensing strategy.

At the firm, Sherry brings in deep pharmaceutical development expertise and hands-on due diligence experience across research, translational, and clinical domains. She leads scientific evaluations of external assets, assessing development feasibility and informing licensing strategy.

Sherry holds a Ph.D. in Molecular Biology from Yale University, a Master’s degree from the Shanghai Institute of Biochemistry, and a Bachelor’s degree in Biochemistry from Sichuan University.